NysnoBio Publishes in Science Advances
San Francisco | August 27, 2025 – NysnoBio, and sister company FinsnoBio, are developing mitophagy enhancers using gene therapy and small molecule approaches based on genetic targets in Parkinson’s disease.
Along with our colleagues at Caltech, we report a new mechanism of action for small molecule mitophagy activating compounds.
Diagram detailing the proposed mechanism of FB231 and MTK458 in activation of the PINK1/Parkin pathway.
We find that these compounds enhance mitophagy through a dual mechanism, supporting a model whereby weak mitochondrial stress can enhance PINK1/Parkin-mediated mitophagy.
Diagram detailing the activation of the ISR upon exposure to mitochondrial toxins.
As has been learned from activation of other stress response pathways, like Keap-NRF2 and HSP70/90, low levels of stress can activate highly protective responses. These insights highlight important considerations for therapeutic strategies targeting mitophagy activation in Parkinson’s disease.
Read the full article at Science Advances.
Contact NysnoBio to get involved or learn more:
info@nysnobio.com
